US 12,324,916 B2
Hybrid control policy for ECAP-servoed neuromodulation
David A. Dinsmoor, North Oaks, MN (US); and Kristin N. Hageman, Dayton, MN (US)
Assigned to Medtronic, Inc., Minneapolis, MN (US)
Filed by Medtronic, Inc., Minneapolis, MN (US)
Filed on Dec. 1, 2021, as Appl. No. 17/457,189.
Claims priority of provisional application 63/136,942, filed on Jan. 13, 2021.
Prior Publication US 2022/0218996 A1, Jul. 14, 2022
Int. Cl. A61N 1/00 (2006.01); A61N 1/05 (2006.01); A61N 1/36 (2006.01); A61N 1/372 (2006.01)
CPC A61N 1/36132 (2013.01) [A61N 1/05 (2013.01); A61N 1/3601 (2013.01); A61N 1/36062 (2017.08); A61N 1/36114 (2013.01); A61N 1/36135 (2013.01); A61N 1/36192 (2013.01); A61N 1/36196 (2013.01); A61N 1/37235 (2013.01)] 23 Claims
OG exemplary drawing
 
1. A method comprising:
receiving, via a sensing electrode located at a target region of a patient, a plurality of evoked compound action potential (ECAP) signals elicited from respective electrical stimuli delivered to the patient during stimulation therapy;
determining, based on the plurality of ECAP signals, an aggressor category for at least some ECAP signals of the plurality of ECAP signals, the aggressor category determined from a plurality of aggressor categories;
determining, based on the aggressor category, a set of control policy parameters that at least partially define closed-loop control adjustment to one or more parameters that define the stimulation therapy; and
controlling delivery of the stimulation therapy according to at least the set of control policy parameters and one or more subsequent ECAP signals.